Healios K.K. Joins NEDO Project to Enhance Stroke Treatment Verification

Healios KK ( (JP:4593) ) has provided an update.

Healios K.K. has been selected as a co-implementing partner in a NEDO project aimed at verifying and validating the safety of treatments for acute ischemic stroke using large language model technology. This initiative involves collaboration with several universities and institutions to develop a system for automatic data collection from electronic medical records, enhancing post-marketing studies and potentially strengthening Healios’s position in the regenerative medicine industry.

More about Healios KK

Healios K.K. is a leading clinical stage biotechnology company in Japan, focusing on regenerative medicine using stem cells. It develops therapies for diseases lacking effective treatments, utilizing both somatic stem cells and iPS cells. Key products include invimestrocel for ischemic stroke and other conditions, and HLCN061, a gene-edited NK cell treatment for solid tumors.

YTD Price Performance: 65.54%

Average Trading Volume: 3,282,925

Technical Sentiment Signal: Sell

Current Market Cap: Yen29.73B

For an in-depth examination of 4593 stock, go to TipRanks’ Stock Analysis page.